Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Study with completed results acquired from Horizon in 2024.
Age
12–16
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Parent or legal guardian is able to provide written informed consent and patient is able to provide written assent if appropriate.
Male and female adolescents aged 12 to 16 years at the time of enrollment.
Diagnosed with JIA, including all the International League of Associations for Rheumatology JIA subtypes: oligoarthritis, polyarthritis (both rheumatoid factor \[RF\]+ and RF-), psoriatic arthritis, enthesitis-related arthritis, undifferentiated arthritis, and systemic arthritis.
Based upon investigator judgment, it is determined appropriate for the patient to undergo 6 months of continuous treatment with VIMOVO.
Body weight \> 31 kg (68.2 lbs) and within the 5th to 95th percentile of body mass index for age.
You may not be if
In systemic JIA patients, presence of systemic features (ie, fever, rheumatoid rash, serositis, lymphadenopathy, macrophage activation syndrome) within 6 months prior to start of study drug.
Currently taking (ie, within 4 weeks prior to start of drug) naproxen \> 20 mg/kg/day or \> 1000 mg total daily dose.
Hemoglobin ≤ 8.5 g/dL.
Individuals who have cardiovascular or cerebrovascular disease, based on history or risk factors.
Any significant hepatic, renal, pulmonary, ophthalmologic, neurologic, or any other medical conditions indicated by medical/surgical history, physical, or laboratory examination that might put the patient at greater risk during the study.
Clareo Health | A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)
